DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NICOTINE
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
505(b)(2) Clinical Trials for Nicotine
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00224419 | Testing Pharmacological Therapies for Pregnant Smokers | Terminated | National Cancer Institute (NCI) | Phase 4 | 2003-06-01 | Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy. |
| OTC | NCT00224419 | Testing Pharmacological Therapies for Pregnant Smokers | Terminated | Duke University | Phase 4 | 2003-06-01 | Nicotine dependence has not been sufficiently addressed in current state-of-the-science cessation interventions for pregnant smokers. The weight of the evidence from the general population of smokers suggests that nicotine replacement therapies may be beneficial cessation aids for pregnant smokers who are unable to stop smoking. The tremendous potential of these therapies for promoting smoking cessation among pregnant women creates a pressing need for decision tools and protocols to encourage treatment adherence that is essential for rigorous evaluation of the effectiveness of OTC NRT when provided as part of prenatal care. The results of this research could be directly translated to the improvement of obstetrical care providers' clinical practices. Medically supervised use of OTC NRT by pregnant smokers is an alternative to continued smoking that has the potential to substantially increase rates of smoking cessation during pregnancy. |
| OTC | NCT00405912 | St. John's Wort for Tobacco Cessation | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-09-01 | After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Nicotine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000284 | Role of Metabolites in Nicotine Dependence (1) - 1 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 1995-02-01 | The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms. |
| NCT00000284 | Role of Metabolites in Nicotine Dependence (1) - 1 | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 1995-02-01 | The purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms. |
| NCT00000288 | Role of Metabolites in Nicotine Dependence (2) - 5 | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 1995-12-01 | The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nicotine
Condition Name
Clinical Trial Locations for Nicotine
Trials by Country
Clinical Trial Progress for Nicotine
Clinical Trial Phase
Clinical Trial Sponsors for Nicotine
Sponsor Name
